发稿单位：Reuters 发稿时间：FEBRUARY 4, 2020 / 9:56 PM 撰 稿 者：Manas Mishra 原文连结：https://reut.rs/2GQOpza 摘要: 美国卫生部 HSS 周二宣布将与再生元制药 (Regeneron Pharmaceuticals, REGN) 合作开发新型冠状病毒的疗法。REGN 在 2017年曾与 HHS 合作开发对抗伊波拉病 毒的药物。 REGN 表示她们将专注於开发对抗感染的单株抗体 (monoclonal antibodies)。 除 REGN 外，目前已有 Moderna, Gilead, Johnson & Johnson 宣布将投入开发对 抗新型冠状病毒的药物。 (Reuters) - The U.S. Department of Health and Human Services said on Tuesday it was partnering with Regeneron Pharmaceuticals Inc (REGN.O) to develop a treatment for the coronavirus, making the drugmaker the latest to join the race to develop a therapy. The move expands on a previous agreement with the company in 2017 to develop treatments for pathogens that pose significant risk to the public. Regeneron had partnered with an HHS unit to develop treatments for Ebola in 2017. The drugmaker will use the same technology that was used to develop an experimental drug to treat Ebola in the Democratic Republic of Congo, the agency said. Regeneron said it would focus on developing infection-fighting proteins known as monoclonal antibodies. Moderna Inc (MRNA.O), Gilead Sciences Inc (GILD.O), Johnson & Johnson (JNJ.N) have also announced plans to begin work on a treatment for the outbreak, which has affected over 20,000 people in China. --

※ 发信站: 批踢踢实业坊(ptt.cc), 来自: 1.169.215.121 (台湾) ※ 文章网址: https://webptt.com/cn.aspx?n=bbs/nCoV2019/M.1580827505.A.847.html